Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier P Gisbert

Showing results (311-320 of 668) with videos related to

Pageof 67
Sort By:
Helicobacter|April 2, 2026
Helicobacter pylori Eradication Primary Care First-Line Prescriptions: Data From 200,000 Patients in a Real-World CohortEncarnación Fernández-Antón, Olga P Nyssen, Gabriela Alonso-Martínez, et al.
Current Medical Research and Opinion|August 7, 2023
Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in EuropeJavier P Gisbert, Petra Streit, Isabel Redondo, et al.
The Israel Medical Association Journal : IMAJ|January 14, 2021
European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in IsraelDoron Boltin, Zaza Beniashvili, Adi Lahat, et al.
Gastroenterology|April 11, 2021
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysisTheodore Rokkas, Javier P Gisbert, Peter Malfertheiner, et al.
Gastroenterologia Y Hepatologia|February 26, 2013
[Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]José Luis Cabriada, Isabel Vera, Eugeni Domènech, et al.
Gastroenterologia Y Hepatologia|December 17, 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitisDaniel Ginard, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, et al.
Medicina Clinica|September 15, 2005
[Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]Javier P Gisbert, Fernando Gomollón, Carlos Cara, et al.
Digestive Diseases and Sciences|March 6, 2007
Thiopurine methyltransferase activity in Spain: a study of 14,545 patientsJavier P Gisbert, Fernando Gomollón, Carlos Cara, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 23, 2017
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel diseaseJames O Lindsay, Alessandro Armuzzi, Javier P Gisbert, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg): Most relevant results for clinical practiceOlga P Nyssen, Leticia Moreira, Natalia García-Morales, et al.
Pageof 67

Showing results (311-320 of 668) with videos related to

Sort By:
Pageof 67
Helicobacter|April 2, 2026
Helicobacter pylori Eradication Primary Care First-Line Prescriptions: Data From 200,000 Patients in a Real-World CohortEncarnación Fernández-Antón, Olga P Nyssen, Gabriela Alonso-Martínez, et al.
Current Medical Research and Opinion|August 7, 2023
Clinical profiles and outcomes in patients with ulcerative colitis receiving standard and higher-than-standard doses of vedolizumab: findings from a real-world study in EuropeJavier P Gisbert, Petra Streit, Isabel Redondo, et al.
The Israel Medical Association Journal : IMAJ|January 14, 2021
European Registry on Helicobacter pylori management (Hp-EuReg): First-line Therapy in IsraelDoron Boltin, Zaza Beniashvili, Adi Lahat, et al.
Gastroenterology|April 11, 2021
Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysisTheodore Rokkas, Javier P Gisbert, Peter Malfertheiner, et al.
Gastroenterologia Y Hepatologia|February 26, 2013
[Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease]José Luis Cabriada, Isabel Vera, Eugeni Domènech, et al.
Gastroenterologia Y Hepatologia|December 17, 2019
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitisDaniel Ginard, Ignacio Marín-Jiménez, Manuel Barreiro-de Acosta, et al.
Medicina Clinica|September 15, 2005
[Thiopurine methyltransferase activity in inflammatory bowel disease. A study on 7046 Spanish patients]Javier P Gisbert, Fernando Gomollón, Carlos Cara, et al.
Digestive Diseases and Sciences|March 6, 2007
Thiopurine methyltransferase activity in Spain: a study of 14,545 patientsJavier P Gisbert, Fernando Gomollón, Carlos Cara, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 23, 2017
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel diseaseJames O Lindsay, Alessandro Armuzzi, Javier P Gisbert, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg): Most relevant results for clinical practiceOlga P Nyssen, Leticia Moreira, Natalia García-Morales, et al.
Pageof 67